Chronic Hepatitis B Market Report 2025

This Chronic Hepatitis B market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The chronic hepatitis B market size has grown steadily in recent years. It will grow from $3.77 billion in 2024 to $3.94 billion in 2025 at a compound annual growth rate (CAGR) of 4.5%. The growth in the historic period can be attributed to advances in antiviral therapy, growing government and NGO initiatives, improved diagnostic techniques, the rising prevalence of HIV, and increasing awareness.

The chronic hepatitis B market size is expected to see steady growth in the next few years. It will grow to $4.65 billion in 2029 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to expansion in emerging markets, growing government policies and funding, improved diagnostics and screening, rising healthcare expenditure, increasing strategic collaborations and partnerships, a growing aging population, and growing public awareness campaigns. Major trends in the forecast period include a shift towards curative therapies, expansion in emerging markets, enhanced diagnostics and screening, partnerships and collaborations, and a focus on patient-centric care.

The high prevalence of chronic hepatitis B infection is expected to drive the growth of the chronic hepatitis B virus market in the future. Hepatitis B is a liver infection caused by the hepatitis B virus (HBV) and can be prevented through vaccination. The rise in hepatitis B infection rates is largely due to low vaccination coverage, especially in low- and middle-income countries, leading to higher transmission rates as significant portions of the population remain unprotected. Increasing rates of hepatitis B infection are likely to boost demand for diagnostic tests and treatment options. For instance, according to a report published in June 2024 by the Centers for Disease Control and Prevention (CDC), a US-based government agency, increasing global hepatitis B vaccination coverage to 90% and treatment access to 80% could prevent 26 million new infections and 9 million deaths due to hepatitis B from 2022 to 2050. In 2022 alone, there were 1.2 million new cases of HBV infection. Consequently, the high prevalence of hepatitis B infection is expected to drive growth in the chronic hepatitis B virus market.

Leading companies in the chronic hepatitis B market are prioritizing technological advancements, such as novel antiviral therapies. These innovative therapies target viral infections, including resistant strains, by inhibiting viral replication and incorporating advanced delivery systems, with ongoing clinical trials assessing their safety and efficacy, such as bepirovirsen for chronic hepatitis B. For example, in February 2024, GSK plc, a UK-based multinational pharmaceutical and biotechnology company specializing in the research, development, manufacturing, and marketing of healthcare products, received the U.S. Food and Drug Administration (FDA) Fast Track designation for bepirovirsen, an investigational antisense oligonucleotide (ASO) for chronic hepatitis B (CHB). Bepirovirsen is designed to degrade the RNA of the hepatitis B virus (HBV), potentially enabling the immune system to regain control over the infection. The drug has shown promising results in Phase IIb trials, specifically the B-Clear and B-Sure studies, where it demonstrated efficacy in reducing hepatitis B surface antigen (HBsAg) levels and achieving sustained viral suppression.

In November 2023, GSK plc, a pharmaceutical company headquartered in the UK, acquired exclusive rights to a hepatitis B therapy from Janssen Pharmaceuticals for $1 billion. The acquisition includes the rights to JNJ-3989 (also known as ARO-HBV), an antisense oligonucleotide drug. Through this acquisition, GSK aims to enrich its portfolio and reinforce its position in the treatment of chronic hepatitis B by introducing a promising new therapy. Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson based in Belgium, specializes in developing treatments for a range of serious and complex diseases, including infectious diseases such as chronic hepatitis B.

Major companies operating in the chronic hepatitis b market are Pfizer Inc., F Hoffmann-La Roche Ltd, Merck & Co Inc, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Dynavax Technologies Corporation, Gilead Sciences Inc, Viatris Inc., Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Apotex Corp, Cipla Ltd, Hikma Pharmaceuticals, Lupin Pharmaceuticals Inc, Vir Biotechnology Inc, VBI Vaccines Inc, Shenzhen Hepalink Pharmaceutical Co. Ltd., Accord Healthcare Inc, Par Pharmaceutical Inc, Arrowhead Pharmaceuticals Inc, ViiV Healthcare, Arbutus Biopharma Corporation, Ascentage Pharma, ENYO Pharma, Zydus Pharmaceuticals Inc, Nucorion Pharmaceuticals.

North America was the largest region in the chronic hepatitis B market in 2024. The regions covered in the chronic hepatitis b market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chronic hepatitis b market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Chronic hepatitis B results from a prolonged infection with the hepatitis B virus (HBV), lasting more than six months. It can potentially cause severe liver damage, liver failure, or liver cancer. While often asymptomatic for years, it can be identified through blood tests and requires ongoing management with antiviral medications and regular monitoring.

In treating chronic hepatitis B, medications primarily consist of antivirals and immunomodulators. Antivirals are specifically designed to hinder the replication and growth of viruses. They play a crucial role in managing chronic hepatitis B by reducing the viral load in the liver and slowing the progression of liver damage.

The chronic hepatitis B market research report is one of a series of new reports that provides chronic hepatitis B market statistics, including chronic hepatitis B industry global market size, regional shares, competitors with an chronic hepatitis B market share, detailed chronic hepatitis B market segments, market trends and opportunities, and any further data you may need to thrive in the chronic hepatitis B industry. This chronic hepatitis B market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chronic hepatitis B market consists of revenues earned by entities by providing services such as diagnostic testing, treatments, liver function monitoring, patient education, and support programs.The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic hepatitis B market also includes sales of medications, interferons, liver transplant medications, diagnostic kits, liver biopsy equipment, and HBV vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.